Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation

Gene Therapy

Volumn 15, Issue 19, 2008, Pages 1302-1310

  Kotturi, H S R ^a   Li, J ^b   Branham O'Connor, M ^a   Stickel, S L ^b   Yu, X ^a,b   Wagner, T E ^a,b   Wei, Y ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; FAS ANTIGEN; FASTI ANTIGEN TRANSCRIPTION FACTOR MULT1E FUSION PROTEIN; HYBRID PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; PLASMID VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MULT1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE TARGETING; IN VIVO STUDY; LUNG METASTASIS; LUNG TUMOR; MALE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR CELL; TUMOR REJECTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARCINOMA; CARRIER PROTEINS; CELL LINE, TUMOR; CLONING, MOLECULAR; FEMALE; GENE EXPRESSION; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

ADENOVIRIDAE; MUS;

EID: 52049110547     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.77     Document Type: Article

References (44)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
2. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001; 181: 170-184.
3. Moretta L, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC et al Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
4. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
5. Yokoyama WM, Daniels BF, Seaman WE, Hunziker R, Margulies DH, Smith BR et al. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995; 7: 89-101.
6. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA 2000; 97: 4778-4783.
7. Takei F, McQueen KL, Maeda M, Wilhelm BT, Lohwasser S, Lian RH et al Ly49 and CD94/NKG2: Developmentally regulated expression and evolution. Immunol Rev 2001; 181: 90-103.
8. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001; 19: 291-330.
9. Braud VM, Allan DS, McMichael AJ. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 1999; 11 100-108.
10. Bauer S, Groh V, Wu J, Steinle A, Phillip JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
11. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17: 19-29.
12. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the munne NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-126.
13. Malarkannan S, Shih PP, Eden PA, Horng T, Zuberi AP, Christianson G et al. The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol 1998; 161: 3501-3509.
14. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM. Cutting edge: murine UL16-binding protein-like transcript 1: A newly described transcript encoding a high affinity ligand for murine NKG2D. J Immunol 2002; 169: 4079-4083.
15. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003; 33: 381-391.
16. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
17. Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4: 321-426.
18. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
19. Sahh HP, Rammensee HG, Steinle A. Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169 4098-4102.
20. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994; 57: 371-377.
21. Ivanov VN, Bergami PL, Maulit G, Sato TA, Sassoon D, Ronai Z. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003; 23: 3623-3635.
22. Pith RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P et al Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
23. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. BCL-X, a BCL-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
24. Sarid R, Sat T, Bohenzky RA, Russo JJ, Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nature Med 1997; 3: 293-298.
25. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
26. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000; 97 10872-10877.
27. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 2000; 6 529-535.
28. Soengas MS, Capodieci P, Polsky D. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
29. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 1985; 313: 1485-1492.
30. law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M et al Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell cardnoma. Cancer 1995; 76: 824-832.
31. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA et al. Evaluation of natural killer cell expansion and activation in vitro with daily subcutaneous low-done interleukin-2 plus periodic intermediate dose pulsing. Can Immunul Immunother 1998; 46: 318-326.
32. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
33. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000; 6: 3560-3564.
34. Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer World J Gastroenterol 2003; 9: 1415-1420.
35. Elsasser-Beile U, Gierschner D, Welchner T, Wetterauer U. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas. Anticancer Res 2003; 23: 433-437.
36. Raffaghello, L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-568.
37. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulatim of resting human natural killer cells. Immunol Rev 2006; 214: 73-91.
38. Tassi I, Klesney-Tait J, Colonna M. Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunol Rev 2006; 214: 92-105.
39. Smyth MJ, Hayakawa. Y, Takeda K, Yagita H. New aspects of natural killer cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2 850-851.
40. Diefenbach A, Jesen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413 165-471.
41. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526.
42. Cohen EE, Rudin CM. ONYX-015: Onyx Pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 1770-1775.
43. Ries S, Korn WM. ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5-11.
44. Liu XY. Targeting gene-virotherapy of cancer and its prosperity Cell Res 2006; 16: 879-886.